HER2Delta16 peptides

Patent metadata

Field	Value
Publication number	US-9630993-B2
Application number	US-201514712165-A
Country	US
Kind code	B2
Filing date	May 14, 2015
Priority date	Dec 2, 2010
Publication date	Apr 25, 2017
Grant date	Apr 25, 2017

Abstract

The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.

First claim

What is claimed is:

1. A method of treating a subject having a cancer, wherein the subject has a cancer that expresses HER2Δ16, the method comprising administering to the subject an antibody that specifically binds to an exon 16-deleted HER2 (“HER2Δ16”) cyclic peptide having the structure:

wherein MPA is beta-mercaptopropionic acid.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody is a polyclonal antibody.

4. The method of claim 1 , wherein the antibody is a chimeric antibody.

5. The method of claim 1 , wherein the antibody is a humanized antibody.

6. The method of claim 1 , wherein the subject has a cancer that overexpresses HER2Δ16.

7. The method of claim 1 , wherein the cancer is breast cancer.

8. The method of claim 1 , wherein the antibody is formulated in a pharmaceutically acceptable carrier.

9. The method of claim 1 , wherein the antibody is administered in combination with one or more additional therapeutic agents.

10. The method of claim 9 , wherein the one or more additional therapeutic agents is a chemotherapeutic agent.

Assignees

• Nestec Sa

Inventors

• Ling Nicholas Chi-Kwan

Classifications

• G01N33/57515

  of the breast · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K14/71 Primary

  for growth factors; for growth regulators · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K47/6851

  the antibody targeting a determinant of a tumour cell · CPC title